Abstract 221P
Background
First-line immune checkpoint inhibitor (ICI) for cisplatin-ineligible metastatic urothelial carcinoma patients has been approved by FDA and EMA. However, there is still a lack of evidence to directly compare treatment efficacy between ICI and conventional carboplatin-based chemotherapy. Here we conduct a retrospective analysis to compare the survival outcome between ICI and carboplatin treatment.
Methods
The study enrolled 130 metastatic urothelial carcinoma patients who underwent first-line ICI or carboplatin-based chemotherapy at Kaohsiung and Linko Chang Gung Memorial Hospital between May 2001 and Jun 2019. Kaplan-Meier analyses and Cox proportional regression models were used for univariate and multivariate survival analyses.
Results
In total, there were 44 patients (34%) in the ICI group and 86 patients (66%) in the carboplatin group. The median OS was insignificantly different between ICI and carboplatin groups, accounting for 11.1 and 9.5 months (p = 0.46), respectively. The median PFS in ICI and carboplatin groups were 2.5 and 3.7 months, respectively (p = 0.92). On subgroup analysis, OS was significantly worse for ICI treatment in patients with elevated pretreatment white blood cell count (WBC ≥ 10000 × 103/μL) compared with those on carboplatin group (HR 2.41, 95% CI 1.1 – 5.25, p = 0.03).
Conclusions
In this real-world data analysis, we didn’t show significant survival difference in first-line treatment with ICI and carboplatin-based chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
329P - High-level expression of HDAC10 is associated with PD-L1 expression and poor prognosis in patients with non-small cell lung cancer receiving pulmonectomy
Presenter: Xiaomei Liu
Session: Poster display session
Resources:
Abstract
331P - A retrospective analysis of immune checkpoint therapy in patients with non-small cell lung cancer: Focus on thyroid disorder
Presenter: Sawana Ono
Session: Poster display session
Resources:
Abstract
332P - Analyse the association between adverse events (AEs) and survival in patients treated with immune checkpoint inhibitors (ICIs)
Presenter: Chi-yuan Cheng
Session: Poster display session
Resources:
Abstract
333P - Study of searching on efficacy of immune checkpoint inhibitor for the non-small cell lung cancer using FDG-PET/CT and thallium SPECT
Presenter: KAYOKO Kibata
Session: Poster display session
Resources:
Abstract
334P - Incidence and characteristic of adrenal insufficiency due to immune checkpoint inhibitors therapy
Presenter: Daisuke Etoh
Session: Poster display session
Resources:
Abstract
335P - PD-L1 profile of nasopharyngeal cancer patients in Indonesia
Presenter: Handoko Handoko
Session: Poster display session
Resources:
Abstract
336P - Pembrolizumab plus chemotherapy versus pembrolizumab monotherapy for PD-L1-positive advanced non-small cell lung cancer in the real world
Presenter: Jun Sugisaka
Session: Poster display session
Resources:
Abstract
337P - Neutrophil-to-Lymphocyte ratio as a predictive factor for hyperprogressive disease in NSCLC patients treated with immune checkpoint inhibitor
Presenter: Ryo Takahashi
Session: Poster display session
Resources:
Abstract
338P - A new insight into tumour immune-evasion: Crosstalk between cancer stem cells and T regulatory cells
Presenter: Abhishek Dutta
Session: Poster display session
Resources:
Abstract
339TiP - PACIFIC-5: Phase III study of durvalumab after either concurrent or sequential chemoradiotherapy (CRT) in patients with stage III NSCLC
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract